Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation

INTRODUCTION: Disease‐modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non‐invasive blood‐based biomarker (BBBM) test for detection of amyloid‐β pathology may reduce diagnostic barriers and facilitate DMT initiation. OBJECTIVE: To explore heterogeneity...

Descripción completa

Detalles Bibliográficos
Autores principales: Suridjan, Ivonne, van der Flier, Wiesje M., Monsch, Andreas U., Burnie, Nerida, Baldor, Robert, Sabbagh, Marwan, Vilaseca, Josep, Cai, Dongming, Carboni, Margherita, Lah, James J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696162/
http://dx.doi.org/10.1002/dad2.12508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696162/
http://dx.doi.org/10.1002/dad2.12508

Ejemplares similares